Crinetics Pharmaceuticals (CRNX) Free Cash Flow (2017 - 2026)

Crinetics Pharmaceuticals' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$125.2 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 41.09% year-over-year to -$125.2 million; the TTM figure through Mar 2026 stood at -$414.8 million (down 54.44% YoY), while the FY2025 annual figure was -$378.3 million, down 61.65% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$125.2 million, down from -$93.2 million in the prior quarter.
• The five-year high for Free Cash Flow was -$13.6 million in Q1 2022, with the low at -$125.2 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$46.7 million (2024), against an average of -$60.1 million.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow jumped 32.15% in 2022, then tumbled 198.86% in 2023.
• Crinetics Pharmaceuticals' Free Cash Flow stood at -$33.8 million in 2022, then decreased by 21.95% to -$41.3 million in 2023, then sank by 71.28% to -$70.7 million in 2024, then sank by 31.96% to -$93.2 million in 2025, then plunged by 34.25% to -$125.2 million in 2026.
• Business Quant data shows CRNX's Free Cash Flow at -$125.2 million in Q1 2026, -$93.2 million in Q4 2025, and -$106.3 million in Q3 2025.